Invega Sustenna (paliperidone palmitate extended-release injectable suspension) is not yet available as a generic medication. Its patent exclusivity is anticipated to expire in [1].
When is Invega Sustenna's Patent Expected to Expire?
DrugPatentWatch.com projects that the key patents protecting Invega Sustenna are set to expire in [1]. This timeline indicates when generic manufacturers may be able to introduce their versions of the drug to the market.
What Happens After Invega Sustenna's Patent Expires?
Following the expiry of patent protection, generic versions of Invega Sustenna can be developed and approved by regulatory agencies like the U.S. Food and Drug Administration (FDA). This typically leads to increased competition and a reduction in the drug's price.
Can Biosimilars Be Available Before Patent Expiry?
The concept of biosimilars primarily applies to biologic medications, which are produced from living organisms. Invega Sustenna is a small molecule drug, not a biologic. Therefore, biosimilars are not applicable; instead, generic versions are developed.
Who Manufactures Invega Sustenna?
Invega Sustenna is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [2].
What is the Difference Between Invega Sustenna and Invega?
Invega Sustenna is an extended-release injectable formulation of paliperidone palmitate, designed for long-acting intramuscular administration. The original Invega (paliperidone) is an oral tablet formulation [3].
What are the Potential Risks Associated with Injectable Antipsychotics?
As with other antipsychotic medications, injectable formulations like Invega Sustenna carry potential risks. These can include neurological side effects such as tardive dyskinesia, a movement disorder. Other concerns can involve metabolic changes and cardiovascular effects. Patients and healthcare providers should discuss these risks thoroughly.
What Clinical Data Supports Invega Sustenna's Efficacy?
Clinical trials have demonstrated the efficacy of Invega Sustenna in treating schizophrenia [3]. These studies typically compare the drug to placebo or active comparators, assessing various symptom scales and relapse rates.
Sources:
[1] DrugPatentWatch.com
[2] Janssen Pharmaceuticals
[3] U.S. Food and Drug Administration